14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VNDA vs SLN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas SLN carries 46.9/100 (HOLD) at $19.82 (N/M Forward P/E, -10475.6% operating margin).
Growth vs. Quality Trade-Off: VNDA earns the overall head-to-head edge with a stronger Unified Composite Score (49.0/100 HOLD vs. SLN 46.9/100 HOLD) and 1.25β · 61% Vol risk profile, whereas SLN leads top-line expansion (+197.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile SLN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VNDA vs SLN. Trailing 12-month operating profitability (VNDA -77.6% vs SLN -10475.6%) and valuation multiples (VNDA 103.1x vs SLN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.2B market capitalization and -10475.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VNDA vs SLN Key Questions & Quantitative Answers
As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas SLN carries 46.9/100 (HOLD) at $19.82 (N/M Forward P/E, -10475.6% operating margin). Growth vs. Quality Trade-Off: VNDA earns the overall head-to-head edge with a stronger Unified Composite Score (49.0/100 HOLD vs. SLN 46.9/100 HOLD) and 1.25β · 61% Vol risk profile, whereas SLN leads top-line expansion (+197.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile SLN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SLN leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with SLN at +197.2% YoY revenue growth and +0.0% YoY earnings growth on $615,000 TTM revenue (85.9% gross margin, -10475.6% operating margin). On trailing 12-month operating scale, VNDA generates $229M in USD-normalized revenue versus $615,000 for SLN. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLN.
VNDA screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas SLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus SLN (-90.4% ROE) capital efficiency.
In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, SLN carries 55.4% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.92β · 4% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.